Aaron M Etra, Najla El Jurdi, Nikolaos Katsivelos, Deukwoo Kwon, Stephanie C Gergoudis, George Morales, Nikolaos Spyrou, Steven Kowalyk, Paibel Aguayo-Hiraldo, Yu Akahoshi, Francis Ayuketang Ayuk, Janna Baez, Brian C Betts, Chantiya Chanswangphuwana, Yi-Bin Chen, Hannah K Choe, Zachariah DeFilipp, Sigrun Gleich, Elizabeth O Hexner, William J Hogan, Ernst Holler, Carrie L Kitko, Sabrina Kraus, Monzr M Al Malki, Margaret L MacMillan, Attaphol Pawarode, Francesco Quagliarella, Muna Qayed, Ran Reshef, Tal Schechter-Finkelstein, Ingrid Vasova, Daniel J Weisdorf, Matthias Wölfl, Rachel Young, Ryotaro Nakamura, James L M Ferrara, John E Levine, Shernan G Holtan
Graft-vs-host disease (GVHD) is a major cause of non-relapse mortality (NRM) following allogeneic hematopoietic cell transplant (HCT). Algorithms containing either the GI GVHD biomarker amphiregulin (AREG) or a combination of two GI GVHD biomarkers, (ST2+REG3α) when measured at GVHD diagnosis are validated predictors of NRM risk, but have never been assessed in the same patients using identical statistical methods. We measured serum concentrations of ST2, REG3, and AREG by ELISA at the time of GVHD diagnosis in 715 patients divided by date of transplant into training (2004-2015) and validation (2015-2017) cohorts...
April 19, 2024: Blood Advances